Global Targeted Radionuclide Drug Market Growth (Status and Outlook) 2023-2029

Global Targeted Radionuclide Drug Market Growth (Status and Outlook) 2023-2029

The global Targeted Radionuclide Drug market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Targeted Radionuclide Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Targeted Radionuclide Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Targeted Radionuclide Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Targeted Radionuclide Drug players cover POINT Biopharma, Telix, ITM AG, Bayer AG, Novartis, Lantheus, Curium Pharma, Fusion Pharmaceuticals and RadioMedix, Inc., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

LPI (LP Information)' newest research report, the “Targeted Radionuclide Drug Industry Forecast” looks at past sales and reviews total world Targeted Radionuclide Drug sales in 2022, providing a comprehensive analysis by region and market sector of projected Targeted Radionuclide Drug sales for 2023 through 2029. With Targeted Radionuclide Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Targeted Radionuclide Drug industry.

This Insight Report provides a comprehensive analysis of the global Targeted Radionuclide Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Targeted Radionuclide Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Targeted Radionuclide Drug market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Targeted Radionuclide Drug and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Targeted Radionuclide Drug.

This report presents a comprehensive overview, market shares, and growth opportunities of Targeted Radionuclide Drug market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Medicine
Inhibitor

Segmentation by application
Tumors
Thyroid
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
POINT Biopharma
Telix
ITM AG
Bayer AG
Novartis
Lantheus
Curium Pharma
Fusion Pharmaceuticals
RadioMedix, Inc.
Convergent Therapeutics
IONETIX
Clarity Pharmaceuticals
RayzeBio, Inc
AmbioPharm
Bracco Imaging
Navidea
China Isotope & Radiation Corporation
Yantai Dongcheng
Grand Pharma
Hengrui Medicine
Yunnan Baiyao Group
SmartNuclide Biopharma
Sinotau
Hexin Pharmaceutical

Please note: The report will take approximately 2 business days to prepare and deliver.